← Back to Search

Monoclonal Antibodies

IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection for Malignant Lymphomas

Phase 1

Waitlist Available

Research Sponsored by Innovent Biologics (Suzhou) Co. Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial is testing a new cancer drug to see if it is safe and works better than current treatments.

Eligible Conditions

Malignant Lymphomas

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose Limiting Toxicity (DLT)

Treatment-related Adverse Events (TRAEs)

Secondary outcome measures

PK parameters

Positive rate of ADA and Nab

Positive rate of Circulating Immune Complex

Trial Design

1Treatment groups

Experimental Treatment

Group I: Dose Escalation of IBI322Experimental Treatment1 Intervention

Participants will receive escalating dose levels of IBI322 to determine maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of IBI322

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection

2021

Completed Phase 1

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Innovent Biologics (Suzhou) Co. Ltd.Lead Sponsor

167 Previous Clinical Trials

25,755 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current recruitment rate for participants in this clinical trial?

"Affirmative. The details of this clinical trial, initially posted on January 14th 2021 and last updated on August 23rd 2022, are available to view on clinicaltrials.gov; the study is currently recruiting 51 patients from 4 separate medical sites."

Answered by AI

What is the number of healthcare facilities that are implementing this trial?

"At present, 4 medical sites are accepting participants. Those include Westwood, Los Angeles and Houston in addition to one other institution. Selecting the nearest location can reduce any travel burden associated with taking part in this trial."

Answered by AI

Are there any open vacancies in this research program?

"Clinicaltrials.gov reveals that this medical trial is open and accepting participants. It was initially announced on January 14th 2021, with the most recent amendment made on August 23rd 2022."

Answered by AI

How does the IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection impact patient well-being?

"Due to the lack of clinical data in regards to its safety and efficacy, IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection was given a score of 1."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

2021. "A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04338659.